Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa) Meeting Abstract
| Authors: | Niazi, T.; Nguyen, P. L.; Williams, S.; Stockler, M. R.; Martin, A. J.; Horvath, L.; Thomas, H.; Sinikovic Zebic, D.; Roncolato, F.; Lim, T.; Jose, C.; Martin, J.; Chung, H. T.; Ebacher, A.; Morgan, S. C.; Hughes, S.; McBride, S. M.; Kelly, P. J.; Davis, I. D.; Sweeney, C.; The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) |
| Abstract Title: | Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa) |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900325 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.328 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 328 -- Source: Wos |
